A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation.

about

A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation.

Item

http://www.wikidata.org/entity/Q55366823

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

A comparison of the effect of ...... tic stem cell transplantation.

@en

A comparison of the effect of ...... tic stem cell transplantation.

@nl

type

Item

label

A comparison of the effect of ...... tic stem cell transplantation.

@en

A comparison of the effect of ...... tic stem cell transplantation.

@nl

prefLabel

A comparison of the effect of ...... tic stem cell transplantation.

@en

A comparison of the effect of ...... tic stem cell transplantation.

@nl

P1476

A comparison of the effect of ...... etic stem cell transplantation

@en

P2093

Hebi Jiang

http://www.w3.org/2001/XMLSchema#string

Qixiang Ye

http://www.w3.org/2001/XMLSchema#string

P2860

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.

A critical review of visual analogue scales in the measurement of clinical phenomena.

Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide?

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).

Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.

Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas.

Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.

Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.

P2888

s13052-018-0482-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13052-018-0482-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hua Jiang

P577

2018-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104331315

http://www.w3.org/2001/XMLSchema#string

P698

29855330

http://www.w3.org/2001/XMLSchema#string

P932

5984402

http://www.w3.org/2001/XMLSchema#string